Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "prexxartan is an angiotensin ii receptor blocker arb indicated for hypertension in adults and children six years and older to lower blood pressure lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events primarily strokes and myocardial infarctions 1 1 heart failure nyha class ii iv prexxartan significantly reduces hospitalization for heart failure in patients who are unable to swallow valsartan tablets 1 2 stable left ventricular failure or left ventricular dysfunction following myocardial infarction prexxartan reduces cardiovascular mortality in patients who are unable to swallow valsartan tablets 1 3 prexxartan is indicated for the treatment of hypertension in adults and children six years and older to lower blood pressure lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events primarily strokes and myocardial infarctions these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which valsartan principally belongs there are no controlled trials in hypertensive patients demonstrating risk reduction with valsartan control of high blood pressure should be part of comprehensive cardiovascular risk management including as appropriate lipid control diabetes management antithrombotic therapy smoking cessation exercise and limited sodium intake many patients will require more than one drug to achieve blood pressure goals for specific advice on goals and management see published guidelines such as those of the national high blood pressure education program s joint national committee on prevention detection evaluation and treatment of high blood pressure jnc numerous antihypertensive drugs from a variety of pharmacologic classes and with different mechanisms of action have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality and it can be concluded that it is blood pressure reduction and not some other pharmacologic property of the drugs that is largely responsible for those benefits the largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly elevated systolic or diastolic pressure causes increased cardiovascular risk and the absolute risk increase per mmhg is greater at higher blood pressures so that even modest reductions of severe hypertension can provide substantial benefit relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk so the absolute benefit is greater in patients who are at higher risk independent of their hypertension e g patients with diabetes or hyperlipidemia and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal some antihypertensive drugs have smaller blood pressure effects as monotherapy in black patients and many antihypertensive drugs have additional approved indications and effects e g on angina heart failure or diabetic kidney disease these considerations may guide selection of therapy prexxartan may be used alone or in combination with other antihypertensive agents prexxartan is indicated for the treatment of heart failure nyha class ii iv to reduce the risk of hospitalization for heart failure in patients who are unable to swallow valsartan tablets there is no evidence that valsartan provides added benefits when it is used with an adequate dose of an ace inhibitor see warnings and precautions 5 2 clinical pharmacology 12 3 clinical studies 14 2 prexxartan is indicated to reduce the risk of cardiovascular death in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction who are unable to swallow valsartan tablets see warnings and precautions 5 2 clinical pharmacology 12 3 clinical studies 14 3" ?g. }

• association label "prexxartan is an angiotensin ii receptor blocker arb indicated for hypertension in adults and children six years and older to lower blood pressure lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events primarily strokes and myocardial infarctions 1 1 heart failure nyha class ii iv prexxartan significantly reduces hospitalization for heart failure in patients who are unable to swallow valsartan tablets 1 2 stable left ventricular failure or left ventricular dysfunction following myocardial infarction prexxartan reduces cardiovascular mortality in patients who are unable to swallow valsartan tablets 1 3 prexxartan is indicated for the treatment of hypertension in adults and children six years and older to lower blood pressure lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events primarily strokes and myocardial infarctions these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which valsartan principally belongs there are no controlled trials in hypertensive patients demonstrating risk reduction with valsartan control of high blood pressure should be part of comprehensive cardiovascular risk management including as appropriate lipid control diabetes management antithrombotic therapy smoking cessation exercise and limited sodium intake many patients will require more than one drug to achieve blood pressure goals for specific advice on goals and management see published guidelines such as those of the national high blood pressure education program s joint national committee on prevention detection evaluation and treatment of high blood pressure jnc numerous antihypertensive drugs from a variety of pharmacologic classes and with different mechanisms of action have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality and it can be concluded that it is blood pressure reduction and not some other pharmacologic property of the drugs that is largely responsible for those benefits the largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly elevated systolic or diastolic pressure causes increased cardiovascular risk and the absolute risk increase per mmhg is greater at higher blood pressures so that even modest reductions of severe hypertension can provide substantial benefit relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk so the absolute benefit is greater in patients who are at higher risk independent of their hypertension e g patients with diabetes or hyperlipidemia and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal some antihypertensive drugs have smaller blood pressure effects as monotherapy in black patients and many antihypertensive drugs have additional approved indications and effects e g on angina heart failure or diabetic kidney disease these considerations may guide selection of therapy prexxartan may be used alone or in combination with other antihypertensive agents prexxartan is indicated for the treatment of heart failure nyha class ii iv to reduce the risk of hospitalization for heart failure in patients who are unable to swallow valsartan tablets there is no evidence that valsartan provides added benefits when it is used with an adequate dose of an ace inhibitor see warnings and precautions 5 2 clinical pharmacology 12 3 clinical studies 14 2 prexxartan is indicated to reduce the risk of cardiovascular death in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction who are unable to swallow valsartan tablets see warnings and precautions 5 2 clinical pharmacology 12 3 clinical studies 14 3" assertion.